< Back to previous page
Project
ERA-NET RUS.PLUS - JTC 2019: NANOtechnological TOolkit for multiplexed 3D detection and monitoring of BIOmarker status in breast cancer biopsies (FWOAL1026)
Immunotherapy has entered a phase of broad application in patients with advanced solid tumours. Now it
must demonstrate its greater potential in personalised approaches. A prerequisite for this is the identification
of genetic and proteomic biomarkers as well as the use of novel immunological signatures that take into
account the complex three-dimensional (3D) architecture of the tumour.
For this purpose, NanoToBio is focused on the set-up of a rapid nanotechnological toolkit for multiplex 3D
imaging at cellular resolution that is able to fully characterize the complex tumor-immune microenvironment
in tumour biopsies for patient stratification for specific immunotherapies. The NanoToBio consortium
provides synergistic expertise to establish the clinically relevant nanotool that will be validated for the 3D
detection of a set of known biomarkers in biopsies of breast cancer, the major cause of cancer-related
mortality in women.
The objectives of the NanoToBio project are to:
- develop ultrasensitive multiparametric nanoprobes based on oriented conjugates of Cd-free
photoluminescent nanocrystals (NCs) and single-domain antibodies (sdAbs) technologies
- demonstrate single and multiplex use of NCs-sdAbs nanoprobes for 3D imaging of cells and
microenvironment in breast cancer biopsies for comparison with conventional 2D histology
- validate all components and demonstrate in an operational clinical pathology lab environment the fast and
multiplexed mapping of novel 3D immunological signatures in breast cancer biopsies
The toolkit will supply read-out protocols for simultaneous detection of up to 10 known cancer- and immunerelated biomarkers with at least 10-fold improvement in sensitivity over the best current photonic diagnostic
assays. The toolkit can be transferred to other types of tumours to assess the immunological signatures for a
better understanding of mechanisms underlying the immune response and allocating patients to immunooncological therapies.
must demonstrate its greater potential in personalised approaches. A prerequisite for this is the identification
of genetic and proteomic biomarkers as well as the use of novel immunological signatures that take into
account the complex three-dimensional (3D) architecture of the tumour.
For this purpose, NanoToBio is focused on the set-up of a rapid nanotechnological toolkit for multiplex 3D
imaging at cellular resolution that is able to fully characterize the complex tumor-immune microenvironment
in tumour biopsies for patient stratification for specific immunotherapies. The NanoToBio consortium
provides synergistic expertise to establish the clinically relevant nanotool that will be validated for the 3D
detection of a set of known biomarkers in biopsies of breast cancer, the major cause of cancer-related
mortality in women.
The objectives of the NanoToBio project are to:
- develop ultrasensitive multiparametric nanoprobes based on oriented conjugates of Cd-free
photoluminescent nanocrystals (NCs) and single-domain antibodies (sdAbs) technologies
- demonstrate single and multiplex use of NCs-sdAbs nanoprobes for 3D imaging of cells and
microenvironment in breast cancer biopsies for comparison with conventional 2D histology
- validate all components and demonstrate in an operational clinical pathology lab environment the fast and
multiplexed mapping of novel 3D immunological signatures in breast cancer biopsies
The toolkit will supply read-out protocols for simultaneous detection of up to 10 known cancer- and immunerelated biomarkers with at least 10-fold improvement in sensitivity over the best current photonic diagnostic
assays. The toolkit can be transferred to other types of tumours to assess the immunological signatures for a
better understanding of mechanisms underlying the immune response and allocating patients to immunooncological therapies.
Date:1 Jul 2021 → Today
Keywords:nanocrystals, single domain antibodies, nanobodies, breast cancer, 3D nanophotonic tool, multiplexing
Disciplines:Diagnostics not elsewhere classified, Nanotechnology not elsewhere classified, Oncology not elsewhere classified